Clinical trial
A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of AP-101 in Participants With Sporadic or SOD1-Associated ALS
NCT05039099 is registered in ClinicalTrials.gov with AL-S Pharma as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of AP-101 in Participants With Sporadic or SOD1-Associated ALS
- Lead sponsor
- AL-S Pharma
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- September 2, 2021
- Completion date
- August 13, 2025
- Enrollment
- 73 (actual)
- Sites
- 13
Conditions
As the registry lists them; a condition with its own page is linked.